GlaxoSmithKline Goes Hostile in Bid for Human Genome Sciences

Source: Miyanville, Brett Chase (5/9/12)

"GlaxoSmithKline has launched a hostile bid for Human Genome Sciences, three weeks after the biotech spurned a $2.6B takeover offer."

Miyanville, Brett Chase

GlaxoSmithKline launched a hostile bid for Human Genome Sciences Wednesday, three weeks after the biotech spurned a $2.6 billion takeover offer. Human Genome also put itself up for sale in April after rejecting Glaxo's $13 per share cash offer. Glaxo, which collaborates with Human Genome on drug development, made it clear Wednesday it doesn't want to be part of an auction.

Glaxo "will not participate in Human Genome Sciences' strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares," the UK drug maker says in a statement.

Glaxo didn't raise its offer and Human Genome investors are hardly going to accept that low a bid. Human Genome's stock is already trading higher even with a dip in the stock. The company's shares fell 2% to $14.37 in early-morning trading Wednesday. Glaxo says its offer is a more than 80% premium to Human Genome's stock price before the takeover talk was made public. Good luck with that argument. . .View Full Article

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Imagin Medical Is Bringing Cystoscopy into the 21st Century
Source: Dr. KSS, MD, PhD, for Streetwise Reports (01/21/2021)

Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment."

A Solace to the Stress of the SolarWinds Hack
Source: Jack Hurley for Streetwise Reports (01/21/2021)

Against the backdrop of the massive SolarWinds hack, value investor Jack Hurley discusses his investment thesis for Leonovus Inc, whose products provide an "ironclad level of cybersecurity."

Avinger Shares Rise 40% on Launch of Image-Guided Device to Diagnose and Treat PAD
Source: Streetwise Reports (01/15/2021)

Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease.

Neurosciences Firm Outlines Strategic Priorities for 2021
Source: Streetwise Reports (01/15/2021)

ProMIS Neurosciences discusses its four priority areas in 2021.

This Tiny Digital Healthcare Company's Sales Should Rocket Higher
Source: Matt Badiali for Streetwise Reports (01/06/2021)

Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone.

This Tiny Tech Stock Is Quietly Building a Huge Business in Air Quality
Source: Matt Badiali for Streetwise Reports (01/05/2021)

Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic.

DermTech Shares Rise 32% on Geisinger Health Support for Skin Cancer Test
Source: Streetwise Reports (12/30/2020)

Shares of DermTech Inc. climbed to a new 52-week high after the company reported it has received positive medical coverage by Geisinger Health System for its pigmented lesion assay, a non-invasive test for detecting melanoma.

California Biotech Advances Two COVID-19 Products
Source: Streetwise Reports (12/30/2020)

Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report.

BioTelemetry Shares Beat Higher on Royal Philips $2.8 Billion Buyout Offer
Source: Streetwise Reports (12/18/2020)

Shares of BioTelemetry Inc. rise 16.5% to a new 52-week high after Royal Philips agreed to acquire the company for US$2.8 billion, or US$72.00 per share in an all cash transaction.